Jefferies Upgrades Apellis Pharmaceuticals (APLS) to Buy, 'we're getting off the sidelines post REST'
Tweet Send to a Friend
(Updated - February 5, 2024 4:36 AM EST)
Jefferies analyst Akash Tewari upgraded Apellis Pharmaceuticals (NASDAQ: APLS) from Hold ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Jefferies analyst Akash Tewari upgraded Apellis Pharmaceuticals (NASDAQ: APLS) from Hold ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
